Efficacy, Tolerability, and Safety of Glucagon‐Like Peptide 1 Receptor Agonists (GLP1‐RA) in Kidney Transplant Recipients With Diabetes
Fuente:
Wiley Open Access
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Artículo Open Access |
| Published: |
Wiley
2025
|
| Subjects: | |
| Online Access: | |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1867002283313594368 |
|---|---|
| author | Henry Zelada Mario Campana Kosuke Kawai David Redden Gaurav Agarwal Orlando M. Gutierrez Vineeta Kumar |
| author_facet | Henry Zelada Mario Campana Kosuke Kawai David Redden Gaurav Agarwal Orlando M. Gutierrez Vineeta Kumar Henry Zelada Mario Campana Kosuke Kawai David Redden Gaurav Agarwal Orlando M. Gutierrez Vineeta Kumar |
| collection | Wiley Open Access |
| contents | Efficacy, Tolerability, and Safety of Glucagon‐Like Peptide 1 Receptor Agonists (GLP1‐RA) in Kidney Transplant Recipients With Diabetes Henry Zelada Mario Campana Kosuke Kawai David Redden Gaurav Agarwal Orlando M. Gutierrez Vineeta Kumar Clinical Transplantation ABSTRACTIntroductionUncontrolled diabetes after solid‐organ transplantation has been associated with weight gain, high cardiovascular mortality, and transplant rejection. The current standard of care for uncontrolled diabetes after KT is insulin. Recently GLP1‐RA have been proposed as an adjuvant medication for those with obesity, but there are concerns for side effects and safety.MethodsAdults (n = 50) with diabetes who underwent KT from at a single academic medical center were included. This is a retrospective study of 25 recipients on insulin ± oral antidiabetic medications who initiated GLP1‐RA, and 25 recipients on insulin ± oral agents. Metabolic issues and safety were evaluated before starting GLP1RA, and 6 and 12 months after. The linear mixed effects model was used to evaluate the mean difference in the change in the outcome between the two groups.ResultsKT participants were on average 56 years of age, 64% male, with T2D. The primary outcome of change in weight 12 months after initiation of GLP1‐RA on an average was −10.1 pounds in the GLP1‐RA group, compared to +6.0 pounds in the non‐GLP1‐RA group (p < 0.01), the change in BMI 12 months after initiation of GLP1‐RA on an average was −1.7 kg/m2 in the GLP1‐RA group compared to +1.1 kg/m2 in the non‐GLP1‐RA group (p < 0.01), and the change in creatinine 12 months after starting GLP1‐RA was on average −0.2 mg/dL in the GLP1‐RA group and on average +0.3 mg/dL in the non‐GLP1‐RA group (p < 0.01). The change in proteinuria 12 months after starting GLP1‐RA was on average −128.4 in the GLP1‐RA and on average +15.4 mg/dL in the controls (p < 0.01). The rate of GLP1‐RA discontinuation was 0%.ConclusionsWell‐selected post‐kidney transplant participants demonstrated good tolerance for GLP‐1RA. Participants who took GLP1‐RA had better glycemic control, more weight loss, a decrease in daily insulin requirements, better preservation of kidney function, and reduced proteinuria 12 months after initiation of GLP1‐RA compared to those who did not. GLP1‐RA did not alter tacrolimus levels or doses. 10.1111/ctr.70144 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| doi_str_mv | 10.1111/ctr.70144 |
| format | Artículo Open Access |
| id | wiley_oa_10_1111_ctr_70144 |
| institution | Wiley Open Access |
| license_str_mv | http://onlinelibrary.wiley.com/termsAndConditions#vor |
| publishDate | 2025 |
| publisher | Wiley |
| record_format | wiley_oa |
| spellingShingle | Efficacy, Tolerability, and Safety of Glucagon‐Like Peptide 1 Receptor Agonists (GLP1‐RA) in Kidney Transplant Recipients With Diabetes Henry Zelada Mario Campana Kosuke Kawai David Redden Gaurav Agarwal Orlando M. Gutierrez Vineeta Kumar Clinical Transplantation Efficacy, Tolerability, and Safety of Glucagon‐Like Peptide 1 Receptor Agonists (GLP1‐RA) in Kidney Transplant Recipients With Diabetes Henry Zelada Mario Campana Kosuke Kawai David Redden Gaurav Agarwal Orlando M. Gutierrez Vineeta Kumar Clinical Transplantation ABSTRACTIntroductionUncontrolled diabetes after solid‐organ transplantation has been associated with weight gain, high cardiovascular mortality, and transplant rejection. The current standard of care for uncontrolled diabetes after KT is insulin. Recently GLP1‐RA have been proposed as an adjuvant medication for those with obesity, but there are concerns for side effects and safety.MethodsAdults (n = 50) with diabetes who underwent KT from at a single academic medical center were included. This is a retrospective study of 25 recipients on insulin ± oral antidiabetic medications who initiated GLP1‐RA, and 25 recipients on insulin ± oral agents. Metabolic issues and safety were evaluated before starting GLP1RA, and 6 and 12 months after. The linear mixed effects model was used to evaluate the mean difference in the change in the outcome between the two groups.ResultsKT participants were on average 56 years of age, 64% male, with T2D. The primary outcome of change in weight 12 months after initiation of GLP1‐RA on an average was −10.1 pounds in the GLP1‐RA group, compared to +6.0 pounds in the non‐GLP1‐RA group (p < 0.01), the change in BMI 12 months after initiation of GLP1‐RA on an average was −1.7 kg/m2 in the GLP1‐RA group compared to +1.1 kg/m2 in the non‐GLP1‐RA group (p < 0.01), and the change in creatinine 12 months after starting GLP1‐RA was on average −0.2 mg/dL in the GLP1‐RA group and on average +0.3 mg/dL in the non‐GLP1‐RA group (p < 0.01). The change in proteinuria 12 months after starting GLP1‐RA was on average −128.4 in the GLP1‐RA and on average +15.4 mg/dL in the controls (p < 0.01). The rate of GLP1‐RA discontinuation was 0%.ConclusionsWell‐selected post‐kidney transplant participants demonstrated good tolerance for GLP‐1RA. Participants who took GLP1‐RA had better glycemic control, more weight loss, a decrease in daily insulin requirements, better preservation of kidney function, and reduced proteinuria 12 months after initiation of GLP1‐RA compared to those who did not. GLP1‐RA did not alter tacrolimus levels or doses. 10.1111/ctr.70144 http://onlinelibrary.wiley.com/termsAndConditions#vor |
| title | Efficacy, Tolerability, and Safety of Glucagon‐Like Peptide 1 Receptor Agonists (GLP1‐RA) in Kidney Transplant Recipients With Diabetes |
| topic | Clinical Transplantation |
| url | https://onlinelibrary.wiley.com/doi/10.1111/ctr.70144 |